$392 Million is the total value of GREAT POINT PARTNERS LLC's 35 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 87.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VNDA | Buy | VANDA PHARMACEUTICALS INC. CMN | $45,030,000 | +48.7% | 2,706,134 | +0.0% | 11.48% | +32.5% |
| ADMS | Buy | ADAMAS PHARMACEUTICALS INC CMN | $42,688,000 | +33.7% | 2,601,351 | +23.3% | 10.89% | +19.1% |
| SGYPQ | Sell | SYNERGY PHARMACEUTICALS INC CMN | $35,386,000 | +22.7% | 6,422,232 | -15.4% | 9.02% | +9.3% |
| ZGNX | ZOGENIX INC CMN | $27,900,000 | +42.0% | 2,440,959 | 0.0% | 7.12% | +26.5% | |
| FOMX | Buy | FOAMIX PHARMACEUTICALS LIMITED CMN | $25,645,000 | +1369.6% | 2,769,425 | +908.0% | 6.54% | +1208.2% |
| DERM | Sell | DERMIRA INC CMN | $22,977,000 | -1.8% | 679,403 | -15.1% | 5.86% | -12.6% |
| RXDX | Buy | IGNYTA INC CMN | $21,859,000 | +24.5% | 3,475,227 | +7.3% | 5.58% | +10.9% |
| ENTA | Buy | ENANTA PHARMACEUTICALS INC CMN | $21,022,000 | +77.2% | 790,000 | +46.8% | 5.36% | +57.8% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC CMN | $19,956,000 | -6.6% | 394,080 | -16.2% | 5.09% | -16.8% |
| AVXS | New | AVEXIS INC CMN | $15,703,000 | – | 381,095 | +100.0% | 4.00% | – |
| MACK | New | MERRIMACK PHARMACEUTICALS INC CMN | $15,508,000 | – | 2,442,159 | +100.0% | 3.96% | – |
| CLCD | New | COLUCID PHARMACEUTICALS INC CMN | $15,260,000 | – | 400,000 | +100.0% | 3.89% | – |
| BVX | BOVIE MEDICAL CORPORATION CMN | $13,963,000 | +217.7% | 2,680,000 | 0.0% | 3.56% | +182.8% | |
| SAGE | Sell | SAGE THERAPEUTICS, INC CMN | $12,198,000 | +22.7% | 264,893 | -19.7% | 3.11% | +9.3% |
| CNXR | CONNECTURE INC | $7,759,000 | -16.8% | 4,127,232 | 0.0% | 1.98% | -25.9% | |
| ARDMQ | ARADIGM CORP CMN | $6,900,000 | +57.4% | 1,002,962 | 0.0% | 1.76% | +40.2% | |
| OCRX | OCERA THERAPEUTICS INC CMN CLASS | $5,184,000 | +38.9% | 1,963,777 | 0.0% | 1.32% | +23.8% | |
| DBVT | New | DBV TECHNOLOGIES SA SPONSORED ADR CMN | $4,776,000 | – | 131,452 | +100.0% | 1.22% | – |
| SNSS | New | SUNESIS PHARMACEUTICALS INC CMN | $4,648,000 | – | 1,063,573 | +100.0% | 1.18% | – |
| ALIM | New | ALIMERA SCIENCES CMN | $3,931,000 | – | 2,637,969 | +100.0% | 1.00% | – |
| BCRX | New | PUT/BCRX @ 5 EXP 03/17/2017put | $3,197,000 | – | 725,000 | +100.0% | 0.82% | – |
| GWPH | New | PUT/GWPH @ 95 EXP 10/21/2016put | $3,159,000 | – | 23,800 | +100.0% | 0.81% | – |
| DPRX | Buy | DIPEXIUM PHARMACEUTICALS INC CMN | $2,594,000 | +197.8% | 178,930 | +103.5% | 0.66% | +165.9% |
| TENX | TENAX THERAPEUTICS INC CMN | $2,568,000 | -9.5% | 1,108,593 | 0.0% | 0.66% | -19.4% | |
| PDLI | New | PDL BIOPHARMA INC CMN | $2,161,000 | – | 645,000 | +100.0% | 0.55% | – |
| TTPH | Sell | TETRAPHASE PHARMACEUTICALS INC CMN | $1,733,000 | -82.5% | 452,375 | -80.3% | 0.44% | -84.4% |
| CATB | New | CATABASIS PHARMACEUTICALS, INC CMN | $1,540,000 | – | 250,000 | +100.0% | 0.39% | – |
| MRTX | New | MIRATI THERAPEUTICS INC CMN | $1,505,000 | – | 227,657 | +100.0% | 0.38% | – |
| MCRB | PUT/MCRB @ 20 EXP 10/21/2016put | $1,475,000 | -57.7% | 120,000 | 0.0% | 0.38% | -62.3% | |
| MCRB | New | SERES THERAPEUTICS, INC. CMN | $1,475,000 | – | 120,000 | +100.0% | 0.38% | – |
| ITEK | New | INOTEK PHARMACEUTICALS CORP CMN | $892,000 | – | 94,077 | +100.0% | 0.23% | – |
| NVAX | New | CALL/NVAX @ 8 EXP 10/21/2016call | $851,000 | – | 409,200 | +100.0% | 0.22% | – |
| STRM | STREAMLINE HEALTH SOLUTNS, INC CMN | $279,000 | +53.3% | 151,611 | 0.0% | 0.07% | +36.5% | |
| ARDX | Buy | ARDELYX INC CMN | $194,000 | +546.7% | 15,000 | +335.5% | 0.05% | +444.4% |
| OPHT | New | CALL/OPHT @ 80 EXP 01/20/2017call | $157,000 | – | 3,400 | +100.0% | 0.04% | – |
| AMRN | Exit | AMARIN CORP PLCspon adr new | $0 | – | -2,000 | -100.0% | -0.00% | – |
| RIGL | Exit | RIGEL PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.03% | – |
| RVNC | Exit | REVANCE THERAPEUTICS INC | $0 | – | -21,665 | -100.0% | -0.08% | – |
| AXGT | Exit | AXOVANT SCIENCES LTD | $0 | – | -25,000 | -100.0% | -0.09% | – |
| PRTK | Exit | PARATEK PHARMACEUTICALS INC | $0 | – | -29,266 | -100.0% | -0.12% | – |
| VCEL | Exit | VERICEL CORP | $0 | – | -253,502 | -100.0% | -0.16% | – |
| CLBS | Exit | CALADRIUS BIOSCIENCES INC | $0 | – | -1,525,244 | -100.0% | -0.26% | – |
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -76,511 | -100.0% | -0.29% | – |
| ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -550,116 | -100.0% | -0.50% | – |
| ITCI | Exit | INTRA CELLULAR THERAPIES INC | $0 | – | -100,000 | -100.0% | -1.11% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -8,173,937 | -100.0% | -1.28% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INCcall | $0 | – | -238,900 | -100.0% | -1.30% | – |
| RPTP | Exit | RAPTOR PHARMACEUTICAL CORP | $0 | – | -978,350 | -100.0% | -1.50% | – |
| ADHD | Exit | ALCOBRA LTD | $0 | – | -1,414,573 | -100.0% | -1.82% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INC | $0 | – | -2,457,144 | -100.0% | -2.06% | – |
| XNCR | Exit | XENCOR INC | $0 | – | -450,000 | -100.0% | -2.45% | – |
| EGRX | Exit | EAGLE PHARMACEUTICALS INC | $0 | – | -548,290 | -100.0% | -6.09% | – |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -500,000 | -100.0% | -6.20% | – |
| EXEL | Exit | EXELIXIS INC | $0 | – | -3,200,000 | -100.0% | -7.16% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.